Odronextamab

奥尼妥单抗

Report date: 2026/05/12 20:00:17

Base Information

Drug NameOdronextamab
Drug Alias NameORDSPONOOrdsponoREGN-1979ZL-1307
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3CD20-directed cytolytic effectsAnti-CD20 +[4] 
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularPlasmablastic Lymphoma +[9] 
Global Approved IndicationsLymphoma, Follicular
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2024/08/22
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Ireland Designated Activity CompanyZai Lab LtdZai Lab (Shanghai) Co Ltd +[8] 
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularPlasmablastic Lymphoma +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG